The effect of HLA-B27 on susceptibility and severity of COVID-19

James T. Rosenbaum; Hedley Hamilton; Michael H. Weisman; John D. Reveille; Kevin L. Winthrop; Dongseok Choi

doi:10.3899/JRHEUM.200939

The effect of HLA-B27 on susceptibility and severity of COVID-19

James T. Rosenbaum, Hedley Hamilton, Michael H. Weisman, John D. Reveille, Kevin L. Winthrop, Dongseok Choi

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	621-622
Number of pages	2
Journal	Journal of Rheumatology
Volume	48
Issue number	4
DOIs	https://doi.org/10.3899/JRHEUM.200939
State	Published - Apr 1 2021

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/JRHEUM.200939

Cite this

@article{4bdb8ebcd03e4778bac535bb980099fe,

title = "The effect of HLA-B27 on susceptibility and severity of COVID-19",

author = "Rosenbaum, {James T.} and Hedley Hamilton and Weisman, {Michael H.} and Reveille, {John D.} and Winthrop, {Kevin L.} and Dongseok Choi",

note = "Funding Information: James T. Rosenbaum1,2, MD Hedley Hamilton3, BSc Michael H. Weisman4, MD John D. Reveille5, MD Kevin L. Winthrop6, MD, MPH Dongseok Choi6, PhD 1Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; 2Legacy Devers Eye Institute, Portland, Oregon, USA; 3Any-3, London, UK; 4Cedars Sinai Medical Center, Los Angeles, California, USA; 5Department of Medicine, University of Texas, Houston, Texas, USA; 6OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from AbbVie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: [email protected].",

year = "2021",

month = apr,

day = "1",

doi = "10.3899/JRHEUM.200939",

language = "English (US)",

volume = "48",

pages = "621--622",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "4",

}

TY - JOUR

T1 - The effect of HLA-B27 on susceptibility and severity of COVID-19

AU - Rosenbaum, James T.

AU - Hamilton, Hedley

AU - Weisman, Michael H.

AU - Reveille, John D.

AU - Winthrop, Kevin L.

AU - Choi, Dongseok

N1 - Funding Information: James T. Rosenbaum1,2, MD Hedley Hamilton3, BSc Michael H. Weisman4, MD John D. Reveille5, MD Kevin L. Winthrop6, MD, MPH Dongseok Choi6, PhD 1Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; 2Legacy Devers Eye Institute, Portland, Oregon, USA; 3Any-3, London, UK; 4Cedars Sinai Medical Center, Los Angeles, California, USA; 5Department of Medicine, University of Texas, Houston, Texas, USA; 6OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from AbbVie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: [email protected].

PY - 2021/4/1

Y1 - 2021/4/1

UR - http://www.scopus.com/inward/record.url?scp=85099742672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099742672&partnerID=8YFLogxK

U2 - 10.3899/JRHEUM.200939

DO - 10.3899/JRHEUM.200939

M3 - Letter

C2 - 33060311

AN - SCOPUS:85099742672

SN - 0315-162X

VL - 48

SP - 621

EP - 622

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 4

ER -

The effect of HLA-B27 on susceptibility and severity of COVID-19

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this